Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 4 × surufatinib × Endocrine × Clear all

Phase

Phase 2 4 Phase 1/2 3 Phase 3 2 Phase 4 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1 Endocrine 1

Conditions

Neuroendocrine Tumors 1

Interventions

Octreotide 5 lanreotide 4 Everolimus 3 Dexmedetomidine 3 Cabergoline 3 pasireotide 2 Phenoxybenzamine 2 trametinib 1 testosterone enanthate 1 surufatinib 1 selpercatinib 1 pralsetinib 1 pegvisomant 1 lutetium Lu 177 dotatate 1 lenvatinib 1 larotrectinib 1 gadoteridol 1 gadoterate meglumine 1 gadolinium ethoxybenzyl DTPA 1 gadodiamide 1 gadobutrol 1 gadobenic acid 1 entrectinib 1 dabrafenib 1 candesartan 1 arginyllysine 1 anlotinib 1 Vitamin D 1 Trimethoprim 1 Thyroid (USP) 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07272512 2025-12-19

ZSPAC-17

Shanghai Zhongshan Hospital

Phase 4 Recruiting

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡